Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epix Pegs Vasovist Approval In Second Half 2007 Following Second “Approvable” Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s action letter for the vascular imaging agent requires an additional clinical trial and a re-read of images from previous trials.

You may also be interested in...



Epix Says FDA Will Take More Time to Review Vasovist Appeal

Company expects to hear a response to the appeal from agency in September.

Epix Says FDA Will Take More Time to Review Vasovist Appeal

Company expects to hear a response to the appeal from agency in September.

Epix Launches Appeal For FDA Approval Of Vasovist

Epix is seeking an advisory committee review of its Vasovist imaging agent, which will be marketed by Schering AG if approved.

Related Content

Topics

UsernamePublicRestriction

Register

PS061305

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel